1353 GMT - Sanofi has investors worried about its lack of a pipeline to replace blockbuster sales of its Dupixent drug once the medicine goes off patent, but it has financial muscle to pursue deals, Jefferies analysts say. "The question remains how to deal with the Dupixent loss of exclusivity after 2030, which, at this point, will have to largely be an inorganic answer. That in and of itself may not be exciting, but the stock is priced for no answer," the analysts say. It should only take one sensible deal to address the market's concern, they add. The French drugmaker should have between 20 billion and 30 billion euros to spend on deals, according to Jefferies. Shares rise 1.6%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments